High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors

  1. Antoine Marçais  Is a corresponding author
  2. Marie Marotel
  3. Sophie Degouve
  4. Alice Koenig
  5. Sébastien Fauteux-Daniel
  6. Annabelle Drouillard
  7. Heinrich Schlums
  8. Sébastien Viel
  9. Laurie Besson
  10. Omran Allatif
  11. Mathieu Bléry
  12. Eric Vivier
  13. Yenan Bryceson
  14. Olivier Thaunat
  15. Thierry Walzer  Is a corresponding author
  1. International Center for Infectiology Research (CIRI), France
  2. Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden
  3. Innate Pharma, France
  4. Aix Marseille Université, France

Abstract

NK cell education is the process through which chronic engagement of inhibitory NK cell receptors by self MHC-I molecules preserves cellular responsiveness. The molecular mechanisms responsible for NK cell education remain unclear. Here, we show that mouse NK cell education is associated with a higher basal activity of the mTOR/Akt pathway, commensurate to the number of educating receptors. This higher activity was dependent on the SHP-1 phosphatase and essential for the improved responsiveness of reactive NK cells. Upon stimulation, the mTOR/Akt pathway amplified signaling through activating NK cell receptors by enhancing calcium flux and LFA-1 integrin activation. Pharmacological inhibition of mTOR resulted in a proportional decrease in NK cell reactivity. Reciprocally, acute cytokine stimulation restored reactivity of hyporesponsive NK cells through mTOR activation. These results demonstrate that mTOR acts as a molecular rheostat of NK cell reactivity controlled by educating receptors and uncover how cytokine stimulation overcomes NK cell education.

Article and author information

Author details

  1. Antoine Marçais

    International Center for Infectiology Research (CIRI), Lyon, France
    For correspondence
    antoine.marcais@inserm.fr
    Competing interests
    No competing interests declared.
  2. Marie Marotel

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  3. Sophie Degouve

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  4. Alice Koenig

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  5. Sébastien Fauteux-Daniel

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  6. Annabelle Drouillard

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  7. Heinrich Schlums

    Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  8. Sébastien Viel

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  9. Laurie Besson

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  10. Omran Allatif

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  11. Mathieu Bléry

    Innate Pharma, Marseille, France
    Competing interests
    Mathieu Bléry, MB is employee of Innate-Pharma.
  12. Eric Vivier

    Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Marseille, France
    Competing interests
    Eric Vivier, EV is shareholder of Innate-Pharma.
  13. Yenan Bryceson

    Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  14. Olivier Thaunat

    International Center for Infectiology Research (CIRI), Lyon, France
    Competing interests
    No competing interests declared.
  15. Thierry Walzer

    International Center for Infectiology Research (CIRI), Lyon, France
    For correspondence
    thierry.walzer@inserm.fr
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0857-8179

Funding

Agence Nationale de la Recherche (ANR-16-CE15-0005-01 Bank)

  • Antoine Marçais

H2020 European Research Council (281025 Dironaki)

  • Thierry Walzer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was carried out in accordance with the French recommendations in the Guide for the ethical evaluation of experiments using laboratory animals and the European guidelines 86/609/CEE. All experimental studies were approved by the bioethic local committee CECCAPP (Permit number: CECCAPP_ENS_2014_018).

Reviewing Editor

  1. Wayne M Yokoyama, Howard Hughes Medical Institute, Washington University School of Medicine, United States

Publication history

  1. Received: February 28, 2017
  2. Accepted: August 29, 2017
  3. Accepted Manuscript published: September 6, 2017 (version 1)
  4. Version of Record published: October 4, 2017 (version 2)

Copyright

© 2017, Marçais et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,305
    Page views
  • 640
    Downloads
  • 36
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Antoine Marçais
  2. Marie Marotel
  3. Sophie Degouve
  4. Alice Koenig
  5. Sébastien Fauteux-Daniel
  6. Annabelle Drouillard
  7. Heinrich Schlums
  8. Sébastien Viel
  9. Laurie Besson
  10. Omran Allatif
  11. Mathieu Bléry
  12. Eric Vivier
  13. Yenan Bryceson
  14. Olivier Thaunat
  15. Thierry Walzer
(2017)
High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors
eLife 6:e26423.
https://doi.org/10.7554/eLife.26423

Further reading

    1. Immunology and Inflammation
    Magdalena Shumanska, Ivan Bogeski
    Insight

    The oxidative state of a critical cysteine residue determines the enzymatic activity of a phosphatase involved in T-cell immune responses.

    1. Immunology and Inflammation
    2. Structural Biology and Molecular Biophysics
    Malcolm JW Sim et al.
    Research Article

    Dimorphic amino acids at positions 77 and 80 delineate HLA-C allotypes into two groups, C1 and C2, which associate with disease through interactions with C1 and C2-specific natural killer cell receptors. How the C1/C2 dimorphism affects T cell recognition is unknown. Using HLA-C allotypes that differ only by the C1/C2-defining residues, we found that KRAS-G12D neoantigen-specific T cell receptors (TCR) discriminated between C1 and C2 presenting the same KRAS-G12D peptides. Structural and functional experiments, and immunopeptidomics analysis revealed that Ser77 in C1 and Asn77 in C2 influence amino acid preference near the peptide C-terminus (pW), including the pW-1 position, in which C1 favors small and C2 prefers large residues. This resulted in weaker TCR affinity for KRAS-G12D-bound C2-HLA-C despite conserved TCR contacts. Thus, the C1/C2 dimorphism on its own impacts peptide presentation and HLA-C restricted T cell responses, with implications in disease, including adoptive T cell therapy targeting KRAS-G12D-induced cancers.